| Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in … EJ Haas, FJ Angulo, JM McLaughlin, E Anis, SR Singer, F Khan, N Brooks, ... The Lancet 397 (10287), 1819-1829, 2021 | 1669 | 2021 |
| Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study SY Tartof, JM Slezak, H Fischer, V Hong, BK Ackerson, ON Ranasinghe, ... The Lancet 398 (10309), 1407-1416, 2021 | 1173 | 2021 |
| Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants L Jódar, J Butler, G Carlone, R Dagan, D Goldblatt, H Käyhty, K Klugman, ... Vaccine 21 (23), 3265-3272, 2003 | 437 | 2003 |
| Development of vaccines against meningococcal disease L Jódar, IM Feavers, D Salisbury, DM Granoff The Lancet 359 (9316), 1499-1508, 2002 | 356 | 2002 |
| Salmonella paratyphi A rates, Asia RL Ochiai, XY Wang, L Von Seidlein, J Yang, ZA Bhutta, SK Bhattacharya, ... Emerging infectious diseases 11 (11), 1764, 2005 | 278 | 2005 |
| Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design JM McLaughlin, Q Jiang, RE Isturiz, HL Sings, DL Swerdlow, BD Gessner, ... Clinical Infectious Diseases 67 (10), 1498-1506, 2018 | 169 | 2018 |
| Streptococcus pneumoniae serotype 19A: worldwide epidemiology R Isturiz, HL Sings, B Hilton, A Arguedas, RR Reinert, L Jodar Expert review of vaccines 16 (10), 1007-1027, 2017 | 139 | 2017 |
| Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative … SY Tartof, JM Slezak, L Puzniak, V Hong, F Xie, BK Ackerson, SR Valluri, ... The Lancet Respiratory Medicine 10 (7), 689-699, 2022 | 124 | 2022 |
| Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries L Jódar, FM LaForce, C Ceccarini, T Aguado, DM Granoff The Lancet 361 (9372), 1902-1904, 2003 | 120 | 2003 |
| Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective … EJ Haas, JM McLaughlin, F Khan, FJ Angulo, E Anis, M Lipsitch, ... The Lancet Infectious Diseases 22 (3), 357-366, 2022 | 111 | 2022 |
| Severity of Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom C Hyams, R Challen, R Marlow, J Nguyen, E Begier, J Southern, J King, ... The Lancet Regional Health–Europe 25, 2023 | 100 | 2023 |
| Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study SY Tartof, JM Slezak, L Puzniak, V Hong, TB Frankland, BK Ackerson, ... The Lancet Regional Health–Americas 9, 2022 | 96 | 2022 |
| Ensuring vaccine safety in immunization programmes—a WHO perspective L Jodar, P Duclos, JB Milstien, E Griffiths, MT Aguado, CJ Clements Vaccine 19 (13-14), 1594-1605, 2001 | 95 | 2001 |
| Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies HL Sings, P De Wals, BD Gessner, R Isturiz, C Laferriere, JM McLaughlin, ... Clinical Infectious Diseases 68 (12), 2135-2143, 2019 | 90 | 2019 |
| Introducing new vaccines into developing countries: obstacles, opportunities and complexities J Clemens, L Jodar Nature Medicine 11 (Suppl 4), S12-S15, 2005 | 85 | 2005 |
| Cholera vaccines for the developing world AL Lopez, JD Clemens, J Deen, L Jodar Human vaccines 4 (2), 165-169, 2008 | 78 | 2008 |
| Putting typhoid vaccination on the global health agenda D DeRoeck, L Jodar, J Clemens New England Journal of Medicine 357 (11), 1069-1071, 2007 | 77 | 2007 |
| Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia RE Isturiz, J Ramirez, WH Self, CG Grijalva, FL Counselman, G Volturo, ... Vaccine 37 (25), 3352-3361, 2019 | 68 | 2019 |
| A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands BD Gessner, Q Jiang, CH Van Werkhoven, HL Sings, C Webber, D Scott, ... Vaccine 37 (38), 5777-5787, 2019 | 64 | 2019 |
| Rates of medically attended RSV among US adults: a systematic review and meta-analysis JM McLaughlin, F Khan, E Begier, DL Swerdlow, L Jodar, AR Falsey Open forum infectious diseases 9 (7), ofac300, 2022 | 62 | 2022 |
